Your browser doesn't support javascript.
loading
Adenoma Detection Rate and Colorectal Cancer Risk in Fecal Immunochemical Test Screening Programs : An Observational Cohort Study.
Zorzi, Manuel; Antonelli, Giulio; Barbiellini Amidei, Claudio; Battagello, Jessica; Germanà, Bastianello; Valiante, Flavio; Benvenuti, Stefano; Tringali, Alberto; Bortoluzzi, Francesco; Cervellin, Erica; Giacomin, Davide; Meggiato, Tamara; Rosa-Rizzotto, Erik; Fregonese, Diego; Dinca, Manuela; Baldassarre, Gianluca; Scalon, Paola; Pantalena, Maurizio; Milan, Luisa; Bulighin, Gianmarco; Di Piramo, Daniele; Azzurro, Maurizio; Gabbrielli, Armando; Repici, Alessandro; Rex, Douglas K; Rugge, Massimo; Hassan, Cesare; Giacomin, Anna; Buda, Andrea; Costa, Deborah; Checchin, Davide; Marin, Renato; Patarnello, Elisabetta; Ceriani, Aldo; Guido, Ennio; Bertomoro, Perla; Merlini, Nicoletta; Murer, Francesca; Ntakirutimana, Ephrem; Benazzato, Luca; Bellocchi, Maria Cristina Conti.
Afiliação
  • Zorzi M; Veneto Tumor Registry, Azienda Zero, Padova, Italy (M.Z., C.B.A., J.B.).
  • Antonelli G; Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, "Sapienza" University of Rome, and Gastroenterology and Digestive Endoscopy Unit, Ospedale dei Castelli Hospital, Ariccia, Rome, Italy (G.A.).
  • Barbiellini Amidei C; Veneto Tumor Registry, Azienda Zero, Padova, Italy (M.Z., C.B.A., J.B.).
  • Battagello J; Veneto Tumor Registry, Azienda Zero, Padova, Italy (M.Z., C.B.A., J.B.).
  • Germanà B; Gastroenterology and Digestive Endoscopy Unit, San Martino Hospital, ULSS 1 Dolomiti, Belluno, Italy (B.G.).
  • Valiante F; Gastroenterology and Digestive Endoscopy Unit, Santa Maria del Prato Hospital, ULSS 1 Dolomiti, Feltre (BL), Italy (F.V.).
  • Benvenuti S; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy (S.B.).
  • Tringali A; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 2 Marca Trevigiana, Conegliano (TV), Italy (A.T.).
  • Bortoluzzi F; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 3 Serenissima, Venezia, Italy (F.B.).
  • Cervellin E; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 3 Serenissima, Dolo (VE), Italy (E.C.).
  • Giacomin D; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 4 Veneto Orientale, San Donà di Piave (VE), Italy (D.G.).
  • Meggiato T; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 5 Rovigo, Italy (T.M.).
  • Rosa-Rizzotto E; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 6 Euganea, Padova, Italy (E.R.-R.).
  • Fregonese D; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 6 Euganea, Camposampiero, Italy (D.F.).
  • Dinca M; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 6 Euganea, Monselice, Italy (M.D.).
  • Baldassarre G; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 7 Pedemontana, Santorso, Italy (G.B.).
  • Scalon P; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 7 Pedemontana, Bassano del Grappa, Italy (P.S.).
  • Pantalena M; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 8 Berica, Arzignano, Italy (M.P.).
  • Milan L; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 8 Berica, Vicenza, Italy (L.M.).
  • Bulighin G; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 9 Scaligera, San Bonifacio, Italy (G.B.).
  • Di Piramo D; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 9 Scaligera, Villafranca, Italy (D. Di P.).
  • Azzurro M; Gastroenterology and Digestive Endoscopy Unit, Azienda ULSS 9 Scaligera, Legnago, Italy (M.A.).
  • Gabbrielli A; Gastroenterology and Digestive Endoscopy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy (A.G.).
  • Repici A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, and IRCCS Humanitas Research Hospital, Endoscopy Unit, Rozzano, Milan, Italy (A.R., C.H.).
  • Rex DK; Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, Indiana (D.K.R.).
  • Rugge M; Veneto Tumor Registry, Azienda Zero, and Department of Medicine DIMED Pathology and Cytopathology Unit, University of Padova, Padova, Italy (M.R.).
  • Hassan C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, and IRCCS Humanitas Research Hospital, Endoscopy Unit, Rozzano, Milan, Italy (A.R., C.H.).
Ann Intern Med ; 176(3): 303-310, 2023 03.
Article em En | MEDLINE | ID: mdl-36802754
ABSTRACT

BACKGROUND:

Colorectal cancer (CRC) screening programs based on fecal immunochemical tests (FITs) represent the standard of care for population-based interventions. Their benefit depends on the identification of neoplasia at colonoscopy after FIT positivity. Colonoscopy quality measured by adenoma detection rate (ADR) may affect screening program effectiveness.

OBJECTIVE:

To examine the association between ADR and postcolonoscopy CRC (PCCRC) risk in a FIT-based screening program.

DESIGN:

Retrospective population-based cohort study.

SETTING:

Fecal immunochemical test-based CRC screening program between 2003 and 2021 in northeastern Italy. PATIENTS All patients with a positive FIT result who had a colonoscopy were included. MEASUREMENTS The regional cancer registry supplied information on any PCCRC diagnosed between 6 months and 10 years after colonoscopy. Endoscopists' ADR was categorized into 5 groups (20% to 39.9%, 40% to 44.9%, 45% to 49.9%, 50% to 54.9%, and 55% to 70%). To examine the association of ADR with PCCRC incidence risk, Cox regression models were fitted to estimate hazard ratios (HRs) and 95% CIs.

RESULTS:

Of the 110 109 initial colonoscopies, 49 626 colonoscopies done by 113 endoscopists between 2012 and 2017 were included. After 328 778 person-years follow-up, 277 cases of PCCRC were diagnosed. Mean ADR was 48.3% (range, 23% and 70%). Incidence rates of PCCRC from lowest to highest ADR group were 13.13, 10.61, 7.60, 6.01, and 5.78 per 10 000 person-years. There was a significant inverse association between ADR and PCCRC incidence risk, with a 2.35-fold risk increase (95% CI, 1.63 to 3.38) in the lowest group compared with the highest. The adjusted HR for PCCRC associated with 1% increase in ADR was 0.96 (CI, 0.95 to 0.98).

LIMITATION:

Adenoma detection rate is partly determined by FIT positivity cutoff; exact values may vary in different settings.

CONCLUSION:

In a FIT-based screening program, ADR is inversely associated with PCCRC incidence risk, mandating appropriate colonoscopy quality monitoring in this setting. Increasing endoscopists' ADR may significantly reduce PCCRC risk. PRIMARY FUNDING SOURCE None.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article